GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines
- Conditions
- Malaria
- Interventions
- Biological: GSK Malaria vaccine 257049
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00443131
- Locations
- π§πͺ
GSK Investigational Site, Gent, Belgium
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Other: Non-interventional study.
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1283
- Registration Number
- NCT00442468
- Locations
- πΊπΈ
GSK Investigational Site, Tacoma, Washington, United States
A Long Term Prospective Follow Up Study For The CATO Study (SAS30018/SER9702)
- Conditions
- Asthma
- Interventions
- Procedure: Symptom ScoreProcedure: Symptom Score and PD20
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 137
- Registration Number
- NCT00441675
- Locations
- π³π±
GSK Investigational Site, Zwolle, Netherlands
Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2009-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1470
- Registration Number
- NCT00441974
- Locations
- π¨π³
GSK Investigational Site, Tianjin, China
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 351
- Registration Number
- NCT00441441
- Locations
- πͺπΈ
GSK Investigational Site, San Javier (Murcia), Spain
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 153
- Registration Number
- NCT00441116
Disturbed Sleep Model Study.
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00440323
- Locations
- π¬π§
GSK Investigational Site, Guildford, Surrey, United Kingdom
Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults
- Conditions
- Hepatitis C, ChronicHepatitis C
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00439959
- Locations
- πΊπΈ
GSK Investigational Site, Evansville, Indiana, United States
A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure
- Conditions
- Depressive Disorder
- Interventions
- Drug: WellbutrinXLDrug: placebo
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00439868
- Locations
- πΊπΈ
GSK Investigational Site, Gainesville, Florida, United States
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Drug: Casopitant/DocetaxelDrug: Docetaxel
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00440128
- Locations
- πΊπΈ
GSK Investigational Site, Lebanon, New Hampshire, United States